Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03732820 · ClinicalTrials.gov registry record · Phase 3

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
895
Enrollment target
20
Study locations

NCT03732820: Active Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.

NCT03732820 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 895 participants, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (384% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03732820, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
895 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Primary Outcome

An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG abiraterone acetate
  • DRUG olaparib

Study Locations (20)

California

  • Research Site - Clovis
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Sacramento
  • Research Site - San Diego

Arizona

  • Research Site - Tucson
  • Research Site - Tucson

Michigan

  • Research Site - Detroit
  • Research Site - Grand Rapids

Alabama

  • Research Site - Birmingham

Alaska

  • Research Site - Anchorage

Colorado

  • Research Site - Denver

Illinois

  • Research Site - Lisle

Indiana

  • Research Site - Jeffersonville

Trial Details

FieldValue
Enrollment Target 895 participants
Start Date 2018-10-31
Est. Completion 2026-04-27
Phase Phase 3
AstraZeneca

1,285 total trials

What the registry record for NCT03732820 still lists

NCT03732820 is an interventional study that assigns participants to a tested intervention. The registered 895 participants enrollment target is mid-sized for trials with a published cap, above the 185-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (384% higher).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which abiraterone acetate is the first listed.

NCT03732820 names 20 study sites across 14 states, led by California, Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT03732820 about?

NCT03732820 is a clinical study titled "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or...

What is the current status of trial NCT03732820?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2018-10-31. Estimated completion is 2026-04-27.

What conditions does trial NCT03732820 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT03732820?

The interventions under investigation include: abiraterone acetate (DRUG), olaparib (DRUG).

Who is sponsoring clinical trial NCT03732820?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03732820 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03732820's enrollment target sits among peer trials

895 5th of 69 higher than 65 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04862663 · 895 participants · Phase 3

    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  • NCT05855200 · 892 participants · Phase 3

    Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03732820, the US trial registry maintained by the National Library of Medicine. NCT03732820 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.